汇宇制药：注射用HY05350获药物临床试验批准

Core Viewpoint - Huiyu Pharmaceutical's wholly-owned subsidiary, Huiyu Haiyue, has received approval from the National Medical Products Administration for the clinical trial of injection HY05350, aimed at treating advanced solid tumors, marking a significant milestone in the company's development of innovative therapies [1] Group 1 - The clinical trial approval is for injection HY05350, which is a self-developed tri-specific antibody TCE product targeting CD3, MSLN, and PD-L1 [1] - HY05350 is classified as a Class 1 innovative therapeutic biological product, indicating its potential as a novel treatment option [1] - As of the announcement date, there are no approved products targeting the same antigens in both domestic and international markets, highlighting the uniqueness of HY05350 [1]